Core Viewpoint - The Guangxi market regulatory authorities have intensified efforts to combat false and illegal medical and pharmaceutical advertisements, achieving significant progress in monitoring and enforcement throughout the year [1][2]. Group 1: Monitoring and Enforcement - The regulatory department has monitored 3.2 million advertisements across various media this year, leading to the investigation of 154 illegal advertisement cases, with nearly 60% being online violations [1] - The focus of enforcement includes four types of illegal activities: fabricating efficacy, exaggerating functions, indirectly publishing medical advertisements, and misusing patient images for endorsements [1] - A total of 13 typical cases have been publicly announced to serve as a warning and educational tool [1] Group 2: Service Reform and Technology Integration - The market regulatory authorities are advancing the convenience of advertisement review services, reducing the approval time for drug, medical device, and health food advertisements from the legal 10 working days to within 3 working days [2] - An "advertisement compliance AI one-click detection app" has been developed to provide users with preliminary compliance assessments and risk alerts for advertisements, aiming to prevent illegal advertisements from the source [2] - The integration of consumer complaint platforms (12315) and government service hotlines (12345) allows for rapid response, tracing, classification, and timely handling of leads related to false and illegal advertisements [2]